Phathom Pharmaceuticals (PHAT) Revenue & Revenue Breakdown
Phathom Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$55.25M
Latest Revenue (Q)
$49.50M
Phathom Pharmaceuticals Revenue by Period
Phathom Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $55.25M | 8001.47% |
| 2023-12-31 | $682.00K | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Phathom Pharmaceuticals generated $55.25M in revenue during NA 2024, up 8001.47% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Phathom Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $49.50M | 25.32% |
| 2025-06-30 | $39.50M | 38.51% |
| 2025-03-31 | $28.52M | -3.86% |
| 2024-12-31 | $29.66M | 81.41% |
| 2024-09-30 | $16.35M | 123.27% |
| 2024-06-30 | $7.32M | 283.05% |
| 2024-03-31 | $1.91M | 180.35% |
| 2023-12-31 | $682.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | - |
Phathom Pharmaceuticals generated $49.50M in revenue during Q3 2025, up 25.32% compared to the previous quarter, and up 675.91% compared to the same period a year ago.
Phathom Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ANAB | AnaptysBio | $91.28M | $76.32M |
| URGN | UroGen Pharma | $90.40M | $27.48M |
| PHAT | Phathom Pharmaceuticals | $55.25M | $49.50M |
| NRIX | Nurix Therapeutics | $54.55M | $7.89M |
| SEPN | Septerna | $1.07M | $21.50M |
| OCS | Oculis | $883.00K | - |
| KOD | Kodiak Sciences | - | - |
| BBOT | BridgeBio Oncology Therapeutics | - | - |
| SANA | Sana Bio | - | - |
| BCAX | Bicara Therapeutics | - | - |
| XNCR | Xencor | - | $43.61M |